GlassScriptPhysician profile
Antesar Zindani
NPI 1134718711
$4,784.79
in general payments reported to CMS, 2019-2025
20 companies · $1,469 in 2025
The $1,469 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $650 · 2024: $2,666 · 2025: $1,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,889 · Travel and Lodging: $896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,888.62 |
| Travel and Lodging | $896.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,458.65 | 2023-2025 | Minimed 780g |
| Novo Nordisk INC | $885.23 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $884.53 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $717.88 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $125.00 | 2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2023 | |
| Sequel Med Tech, LLC | $123.52 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $112.14 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $88.64 | 2023-2025 | Yorvipath |
| Neurocrine Biosciences, INC. | $67.15 | 2025 | |
| Averitas Pharma INC. | $34.71 | 2023-2024 | Qutenza |
| Corcept Therapeutics | $22.40 | 2024 | Korlym |
| Verity Pharmaceuticals INC. | $21.24 | 2024 | Tlando |
| Astellas Pharma US INC | $20.33 | 2023 | Veozah |
| Tolmar, INC. | $19.58 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.37 | 2023 | |
| Boston Scientific Corporation | $16.83 | 2024 | |
| Amneal Pharmaceuticals LLC | $15.76 | 2024 | Unithroid |
| Antares Pharma, INC. | $15.43 | 2023 | Tlando, Xyosted, Nocdurna |
| Cequr Corporation | $13.40 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antesar Zindani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.